Targeting EFGR using anti-EGFR (monoclonal antibodies mAbs) or inhibitors of the kinase domain along with radiation therapy has become a standard therapeutic strategy for HNSCC (Sundvall et al., 2010; Fasano et al., 2021). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.